Holen Sie sich die Stockscreener-App
1.59
1.92%
0.03
Handel nachbörslich:
1.59
Schlusskurs vom Vortag:
$1.56
Offen:
$1.56
24-Stunden-Volumen:
87,838
Relative Volume:
0.32
Marktkapitalisierung:
$68.20M
Einnahmen:
$51.13M
Nettoeinkommen (Verlust:
$-93.80M
KGV:
-0.713
EPS:
-2.23
Netto-Cashflow:
$-129.10M
1W Leistung:
+3.92%
1M Leistung:
+6.00%
6M Leistung:
+32.50%
1J Leistung:
-46.28%
1-Tages-Spanne:
$1.56
$1.59
1-Wochen-Bereich:
$1.48
$1.59
52-Wochen-Spanne:
$0.89
$4.0695
Repare Therapeutics Inc Stock (RPTX) Company Profile
Firmenname
Repare Therapeutics Inc
Sektor
Branche
Telefon
(857) 412-7018
Adresse
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Vergleichen Sie RPTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.59 | 66.05M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-09 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-12 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-17 | Fortgesetzt | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Stifel | Buy |
| 2021-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2020-10-28 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-14 | Eingeleitet | Cowen | Outperform |
| 2020-07-14 | Eingeleitet | Goldman | Neutral |
| 2020-07-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Repare Therapeutics Inc Aktie (RPTX) Neueste Nachrichten
Repare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Candlestick Reversal Detected on Repare Therapeutics Inc.’s ChartScalable Portfolio Growth Suggestions Released - 선데이타임즈
Is Repare Therapeutics Inc. still worth holding after the dipFree Risk-Adjusted Picks With Exit Strategy - Newser
Using portfolio simulators with Repare Therapeutics Inc. includedSafe Investment Ideas with Growth Upside - Newser
Repare Therapeutics (NASDAQ:RPTX) Issues Quarterly Earnings Results - MarketBeat
Is Repare Therapeutics Inc. forming a reversal patternFree Market Surge Signal for Swing Traders - Newser
Backtesting results for Repare Therapeutics Inc. trading strategiesPattern Recognition Based Market Move Prediction - Newser
Is Repare Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSafe Momentum Strategy With Trend Analysis - Newser
Repare Therapeutics Q2 2025 Earnings: EPS Beats Estimates, Revenue Surpasses Expectations - AInvest
Repare Therapeutics Inc (RPTX) Q2 2025 Earnings: EPS of -$0.39 B - GuruFocus
Will Repare Therapeutics Inc. benefit from macro trendsDay Trading Plan with Entry Risk Management - Newser
Analyzing recovery setups for Repare Therapeutics Inc. investorsFree Smart Trend Trading with Weekly Signals - Newser
Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Repare Therapeutics Reports Q2 2025 Results and Strategic Moves - TipRanks
Repare Therapeutics Reports Q2 Earnings: Strategic Moves and Upcoming Data Releases - AInvest
Repare Therapeutics Announces Licensing Deal and Strategic Updates - The Globe and Mail
Repare 2025 Q2 Earnings Strong Improvement as Net Loss Narrows 51.8% - AInvest
Repare Therapeutics Cuts Losses And Snags New Licensing Deals - Finimize
Repare Therapeutics Narrows Losses And Seeks New Paths Forward - Finimize
Repare (RPTX) Q2 Loss Narrows 52% - AOL.com
Repare Therapeutics' Strategic Shift and Milestone-Driven Outlook - AInvest
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year - TipRanks
Repare Therapeutics Inc. SEC 10-Q Report - TradingView
Repare Therapeutics Q2 net loss narrows to $16.7 mln - MarketScreener
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | RPTX Stock News - GuruFocus
Repare Therapeutics reports Q2 2025 revenue $109.5 mln, cash & marketable securities. - AInvest
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - The Globe and Mail
Predicting Repare Therapeutics Inc. trend using moving averagesChart Scanner for Swing Trade Timing - Newser
Repare Therapeutics Provides Business Update and Reports Second - GuruFocus
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Daily Profit Focused Stock Screener - Newser
Can Repare Therapeutics Inc. hit a new high this monthFree Low Risk Swing Trade Opportunity List - Newser
Quantitative breakdown of Repare Therapeutics Inc. recent movePredicted Market Direction Based on Momentum - Newser
What makes Repare Therapeutics Inc. stock price move sharplyUnlock market-leading stock analysis - Jammu Links News
Should I hold or sell Repare Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
Repare Therapeutics Inc. Stock Analysis and ForecastAchieve rapid wealth accumulation with smart picks - Jammu Links News
How volatile is Repare Therapeutics Inc. stock compared to the marketMaximize portfolio value with smart investment plans - Jammu Links News
When is Repare Therapeutics Inc. stock expected to show significant growthAmplify your gains with low-risk picks - Jammu Links News
Does Repare Therapeutics Inc. stock perform well during market downturnsMaximize returns with data-driven strategies - Jammu Links News
Is Repare Therapeutics Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - Jammu Links News
How many analysts rate Repare Therapeutics Inc. as a “Buy”Capitalize on momentum stocks before they peak - Jammu Links News
Finanzdaten der Repare Therapeutics Inc-Aktie (RPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):